Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate

Tiger Newspress2021-10-20

Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate.According to reports, Novavax has been unable to consistently prove it can manufacture a vaccine shot that meets the required quality standards.

The Food and Drug Administration discusses purity levels with each manufacturer, but each batch of the COVID-19 vaccine is supposed to be at least 90% pure.

Novavax has reportedly struggled to maintain purity levels that are close to the 90% threshold. The company recently showed purity levels around the 70% range, per reports. 

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

  • RO8
    2021-10-21
    RO8
    Buy buy buy
  • Jstan
    2021-10-21
    Jstan
    Like too
  • Alan_Goh
    2021-10-20
    Alan_Goh
    Pardon my ignorance .. does Novavax engage a manufacturer to manufacture its vaccine ("fabless")? I know Pfizer has its own manufacturing facilities. Though might be of no fault of Novavax, the time-to-market delay would mean opportunity cost and reputation loss.. I hope the issues can be resolved asap
    • YoungYun: 
      It is mainly because the method used to test the purity of the new crown vaccine does not meet the standards of the regulatory agency.
    • Qqbear: 
      Yes they are partnering with Serum Institute
  • plasticbag
    2021-10-20
    plasticbag
    Ok
  • PanaCota
    2021-10-20
    PanaCota
     Ok
  • BBBBBBBBBB
    2021-10-20
    BBBBBBBBBB
    Ok
发表看法
14